BiotechTube

Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administration

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Papillomavirus Infection

Conditions

Human Papillomavirus Infection

Trial Timeline

Sep 1, 2007 → Aug 1, 2009

NCT ID
NCT00572832

About Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administration

Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administration is a pre-clinical stage product being developed by Merck for Human Papillomavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00572832. Target conditions include Human Papillomavirus Infection.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00572832Pre-clinicalCompleted

Competing Products

20 competing products in Human Papillomavirus Infection

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
52
DolutegravirShionogiPhase 3
77
GSK1349572 + efavirenzShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
33
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
77
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
dolutegravirShionogiPhase 3
77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
77
GSK1349572 + EfavirenzShionogiPhase 1
33
GSK1349572ShionogiPhase 1
33
GSK1349572 + PlaceboShionogiPhase 2
52
Dolutegravir + MethadoneShionogiPhase 1
33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
77
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
33
DTG + BCV + TVRShionogiPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85